Talk:Brahmi

From Charak Samhita
Revision as of 04:41, 17 July 2026 by Agnivesha (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Bacopa monnieri

Brahmi
Section/Chapter Herb database/Brahmi
Botanical name(s) Herpestis monniera Benth.
Family Scrophulariaceae
Availability Available
Contributors Team Dravyaguna
Year of publication 2026
Publisher Charak Samhita Research, Training and Skill Development Centre
DOI Awaited

Brahmi (Bacopa mnonieri) is classified as a "Medhya Rasayana"—a premier rejuvenative tonic believed to nourish the intellect, expand memory capacity, and promote mental longevity.

Nomenclature & Botanical Profile

  • Scientific Name: Bacopa monnieri (L.) Wettst. (Note: Often historically misspelled in literature as Bacopa monneiri).
  • Family: Scrophulariaceae
  • Synonyms: Lysimachia monnieri L., Gratiola monnieri L.
  • Common Names: Brahmi, Water Hyssop, Herb of Grace, Indian Pennywort, Jalabrahmi.
  • Botanical Description: Bacopa monnieri is a perennial, creeping, succulent herb native to the wetlands, marshes, and warm damp regions of India, Asia, Australia, and the Americas. It is characterized by small, oblong, sessile leaves and white-to-pale blue flowers with five petals.

English name

Bacopa, Water hyssop,Thyme Leaved Gratiola,Indian pennywort

Therapeutic uses

Kushtha(skin disease), jwara(fever), shopha(swelling), pandu(anemia), prameha(diabetes ), manasa vikara[1]

Other varieties

Bacopa monniera Hayata & Matsum. Bramia monnieri (L.) Pennell Gratiola monnieria L. Herpestes monnieria (L.) Kunth Herpestis fauriei H.Lev. Herpestis monniera Herpestris monnieria Lysimachia monnieri L. Moniera cuneifolia Michx.

Synonyms in Charak Samhita

Brahmi, Saraswati, Medhya

Synonyms in bhavaprakasa nighantu

Kapotvanka , somavalli(brahmi filled with good qualities)[2]

Varieties

Raja nighantu

Mentioned 2 types[3]

  1. Brahmi
  2. Ksudrapatra brahmi

Ayurvedic pharmacological properties

Properties
Sr.no. Pharmacological criteria Properties
1 Taste (rasa) Bitter (tikta), Astringent (kashaya)
2 Potency (veerya) Cold (sheeta)
3 Post digestion effect (vipaka) Sweet (madhura)
4 Qualities (guna) Light (laghu)
5 Actions (karma) Pacify Kapha and Pitta
6 Extra ordinary effect (prabhava) Brain tonic (Medhya Rasayana)

Reference in Charak Samhita and its actions

Herbs and their activities
Sr.no. Reference in Charak Samhita Activity
1 Cha.Sa.Sutra Sthana 4/9(48) Sandnyasthapana mahakashaya(restoring consciousness)
2 Cha.Sa.Sutra Sthana 4/9(49) Prajasthapana mahakashaya(promoting conception & foetus growth)
3 Cha.Sa.Sharira Sthana 8/20 Garbhasthapana dravyani
4 Cha.Sa.Sharira Sthana 8/58 Stanya dushti chikitsa(treatment of vitiated breast milk)
5 Cha.Sa.Chikitsa Sthana 1/3/24 In formulation of Indra rasayana
6 Cha.Sa.Chikitsa Sthana 7/69 Ingredient in Triphaladi Churna
7 Cha.Sa.Chikitsa Sthana 10/25 Ingredient in Brahmi Ghrita
8 Cha.Sa.Chikitsa Sthana 10/62 In treatment of Atattvabhinivesh
9 Cha.Sa.Chikitsa Sthana 10/64 Ingredient in Atattvabhinivesh nashak yoga
10 Cha.Sa.Chikitsa Sthana 18/40 As a ghrita dravya
11 Cha.Sa.Chikitsa Sthana 23/55 As an ingredient of Mrita sanjivani agada.
12 Cha.Sa.Chikitsa Sthana 23/244 As an ingredient of Amruta ghrita

Dose

  • 1-3 gm in powder form[4]

Important formulations

As per A.P.I.[5]

  • Sarasvatarishta
  • Brahmi ghruta
  • Ratnagiri rasa
  • Brahmi vati
  • Sarasvata churna
  • Smrutisagara rasa

Current availability

Available

Current researches

Active Phytochemical Profile

The therapeutic activity of Bacopa monnieri is predominantly attributed to its complex profile of triterpenoid saponins.

  • Bacoside A: Considered the primary bioactive mixture responsible for cognitive and neuroprotective efficacy. It consists of a mixture of four distinct saponins:
    • Bacoside A3
    • Bacopaside II
    • Bacopaside X (jujubogenin isomer of bacopasaponin C)
    • Bacopasaponin C
  • Bacoside B: A structurally related saponin mixture that assists in overall systemic and cognitive rejuvenation.
  • Alkaloids & Flavonoids: Contains trace alkaloids (brahmine, herpestine) and therapeutic flavonoids (luteolin, apigenin, and quercetin) which exert synergistic antioxidant actions.
  • Bioactive Aglycones: Saponins undergo in vivo transformation into lipophilic aglycones, such as ebelin lactone and bacogenin A1. These aglycones easily cross the blood-brain barrier (BBB) to interact directly with target central nervous system (CNS) receptors.

Pharmacological Mechanisms of Action

                       [ Bacopa monnieri Extract ]
                                    │
         ┌──────────────────────────┼──────────────────────────┐
         ▼                          ▼                          ▼
[ Cholinergic System ]    [ Neuroplasticity / BDNF ]  [ Cellular Protection ]
  • AchE Inhibition         • Dendritic Arborization    • Antioxidant Enzymes (SOD/CAT)
  • Muscarinic Receptor     • NMDA (GluN2B) Expression  • Free Radical Scavenging
    Binding (M1 Activation)                             • Microglial Downregulation

Synaptic Plasticity & Neuronal Arborization

B. monnieri acts directly on neural architecture to promote structural connectivity. Standardized extracts stimulate dendritic arborization and synaptic branching in the basolateral amygdala and CA1 hippocampal subfield. Bacosides upregulate Brain-Derived Neurotrophic Factor (BDNF) and the expression of NMDA receptor subunits (specifically GluN2B), which are vital for establishing long-term potentiation (LTP)—the biological foundation of learning and memory consolidation.

Neurotransmitter Modulation

The cognitive-enhancing properties of Brahmi are highly mediated by the cholinergic system. It modulates acetylcholine (ACh) levels through:

  1. Cholinesterase Inhibition: Exhibits moderate acetylcholinesterase (AChE) inhibition, helping maintain synaptic ACh levels.
  2. Receptor Activation: In silico and in vitro assays show that its active aglycone, ebelin lactone, possesses high binding affinity toward muscarinic (M1) and serotonergic (5-HT2A) receptors, directly enhancing processing capacity.[6]

Antioxidant & Free Radical Scavenging

B. monnieri establishes a highly protective antioxidant defense system in the central nervous system. Bacosides have been shown to upregulate key cellular antioxidant enzymes—including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX)—in the frontal cortex, striatum, and hippocampus.[7] This reduces brain lipid peroxidation, neutralizing oxidative-stress-induced neurodegeneration.

Anti-Amyloidogenic & Anti-Inflammatory Properties

Preclinical evaluations show that B. monnieri protects against toxic protein aggregation, a hallmark of Alzheimer's disease. It actively reduces β-amyloid accumulation and diminishes pro-inflammatory cytokine release (such as TNF-α and IL-6) by downregulating activated microglial cells. It has also demonstrated clear therapeutic pathways in reducing alpha-synuclein aggregation in preclinical models of Parkinson's disease.[8]

Clinical Efficacy & Human Evidence

Bacopa monnieri has been systematically evaluated in numerous double-blind, randomized, placebo-controlled trials (RCTs).[9]

Cognitive Performance & Memory Consolidation

  • Healthy Adults: In a landmark RCT conducted by Stough et al. (2001), 46 healthy adults were administered 300 mg/day of standardized B. monnieri extract (CDRI-08). At 12 weeks of chronic supplementation, the treatment group exhibited a statistically significant improvement in the speed of visual information processing, verbal learning rate, and memory consolidation, coupled with a decrease in state anxiety.[10] Notably, these improvements were absent at the 5-week assessment, illustrating that the cognitive benefits of Brahmi are cumulative and require sustained intake.
  • The Aging Population: To evaluate age-associated cognitive decline, Calabrese et al. (2008) conducted a 12-week RCT on 54 healthy elderly participants (≥ 65 years old) using 300 mg/day of standardized extract. The treatment group experienced highly significant improvements in delayed word recall (Rey Auditory Verbal Learning Test) and attentional performance (Stroop Task reaction times) compared to the placebo group, proving its potential in preventing age-related cognitive decline.[11]
  • Long-Term Memory Retention: These findings are mirrored by Roodenrys et al. (2002), who demonstrated that B. monnieri significantly decreased the rate of forgetting newly acquired information in a cohort of middle-aged adults.[12]

Adaptogenic & Anxiolytic Properties

B. monnieri exhibits robust adaptogenic capabilities by modulating the hypothalamic-pituitary-adrenal (HPA) axis. Clinical studies reveal a significant reduction in serum cortisol levels (the primary physiological stress biomarker) and a reduction in subjective anxiety scores following 8 to 12 weeks of supplementation. This creates a state of "calm alertness" that is highly unique to nootropics.

Summary of Key Therapeutic Indications & Evidence

Therapeutic Area Key Primary Mechanism Clinical / Preclinical Evidence Level of Scientific Certainty
Cognitive Enhancement Dendritic branching, BDNF upregulation, NMDA (GluN2B) expression. Significant improvements in delayed word recall, processing speed, and learning consolidation. High
(Multiple high-quality human RCTs)
Adaptogenic / Anxiolytic Upregulates GABAergic pathways, reduces salivary and serum cortisol. Clinically proven reduction in state-trait anxiety and stress-induced physiological markers. Moderate to High
(Supported by human RCTs)
Neuroprotection Antioxidant enzyme upregulation (SOD, CAT, GPX), free radical scavenging. In vitro & in vivo reduction of lipid peroxidation and structural hippocampal damage. Moderate
(Robust preclinical data; early clinical support)
Anti-Neurodegenerative Interferes with amyloid-β aggregation and reduces microglial pro-inflammatory cytokines. Preclinical reduction of tau phosphorylation and alpha-synuclein aggregation. Emerging
(Requires larger, robust human trials in clinical cohorts)

Dosage, Safety, and Tolerability

  • Clinical Dosage: The standard therapeutic oral dose of B. monnieri extract ranges from 300 to 450 mg per day, typically standardized to contain 20% to 55% active bacosides. In traditional powder form, a daily intake of 5 to 10 grams of crude herb is utilized.
  • Tolerability: B. monnieri is generally characterized by a high therapeutic index and safety profile. It is non-addictive and does not cause sedative or stimulatory withdrawal.
  • Adverse Effects: The most commonly reported side effects in clinical trials are gastrointestinal in nature, including increased stool frequency, mild abdominal cramping, and transient nausea. These effects are expected due to saponin-mediated local irritation and the upregulation of cholinergic activity in the gut. Taking the extract with meals significantly mitigates these effects.
  • Contraindications & Interactions: Due to its cholinergic activity, B. monnieri may exhibit additive effects when co-administered with acetylcholinesterase inhibitors (e.g., donepezil) or cholinergic agonists. Caution is advised for patients taking thyroid medications, as preclinical models suggest mild thyroid hormone-stimulating activity.

References

  1. ↑ Anonymous. The Ayurvedic Pharmacopoeia of India. Department of Ayush, Ministry of Health and Family welfare, Govt. of India, New Delhi, Part I. 1986; Volume 02:11
  2. ↑ Pro. Krushnachandra Chunekar, Bhavaprakash Nighantu. Reprint Edition 2020, Chaukhambha Bharati Academy, guduchyadi varga, verse no.-279
  3. ↑ Dr. Indradev Tripathi , Raja Nighantu of pandit Narhari, ed.2006, Chaukhambha Krishnadas Academy, Varanasi, parpatadi varga verse no- 66,67
  4. ↑ Anonymous. The Ayurvedic Pharmacopoeia of India. Department of Ayush, Ministry of Health and Family welfare, Govt. of India, New Delhi, Part I. 1986; Volume 02:11
  5. ↑ Anonymous. The Ayurvedic Pharmacopoeia of India. Department of Ayush, Ministry of Health and Family welfare, Govt. of India, New Delhi, Part I. 1986; Volume 02:11
  6. ↑ Ramasamy, S., Chin, S. P., Sukumaran, S. D., Buckle, M. J., Kiew, L. V., & Chung, L. Y. (2015). In silico and in vitro analysis of Bacoside A aglycones and its derivatives as the constituents responsible for the cognitive effects of Bacopa monnieri. PLoS One, 10(5), e0126565.
  7. ↑ Bhattacharya, S. K., Bhattacharya, A., Kumar, A., & Ghosal, S. (2000). Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum, and hippocampus. Phytotherapy Research, 14(3), 174-179.
  8. ↑ Jadiya, P., Khan, A., Sammi, S. R., Kaur, S., Mir, S. S., & Nazir, A. (2011). Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson’s disease. Biogerontology, 12(3), 259-271.
  9. ↑ Kongkeaw, C., Dilokthornsakul, P., Thasorsa, P., Limpeanchob, N., & Scholfield, C. N. (2014). Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology, 151(1), 528-535.
  10. ↑ Stough, C., Lloyd, J., Clarke, J., Downey, L. A., Hutchison, C. W., Rodgers, T., & Nathan, P. J. (2001). The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology, 156(4), 481-484.
  11. ↑ Calabrese, C., Gregory, W. L., Leo, M., Kraemer, D., Bone, K., & Oken, B. (2008). Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. The Journal of Alternative and Complementary Medicine, 14(6), 707-713.
  12. ↑ Roodenrys, S., Booth, D., Bulzomi, S., Phipps, A., Micallef, C., & Smoker, J. (2002). Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology, 27(2), 279-281.

External links

IMPPAT Database

Retrieved from "https://www.carakasamhitaonline.com/index.php?title=Talk:Brahmi&oldid=45506"